By: IPP Bureau
Last updated : January 30, 2026 7:15 pm
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
Wanbury Limited has announced the commencement of its cutting-edge API (Active Pharmaceutical Ingredient) facility in Tanuku, Andhra Pradesh, marking a major milestone in the company’s growth trajectory. The facility is expected to generate approximately Rs. 100 crore in revenue and strengthen the company’s global presence.
Commenting on the launch, Mohan Rayana, Director of Wanbury Limited, said, “We are excited about this strategic expansion, which underscores our commitment to meeting global healthcare needs with reliable, high-quality API.”
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules. The company is targeting full commercial production by FY 2026-27.
“This versatile new API is expected to generate incremental revenues for Wanbury in FY 2026-27,” added Rayana. “Together, these four products strengthen our API portfolio and positions the company to capture substantial growth opportunities in domestic and worldwide markets.”
The facility is designed to support both domestic and global commercial production, with state-of-the-art infrastructure capable of meeting high-value pharmaceutical demands. Wanbury plans to deliver additional high-quality APIs by the end of March 2026.
“This project represents strong global performance and reinforces our commitment to the supply of critical APIs,” said Rayana. “The world market for these high-value APIs is expected to grow significantly, and we are well-positioned to capitalize on these opportunities.”
With this launch, Wanbury continues its legacy of innovation in the pharmaceutical sector, positioning the Tanuku facility as a cornerstone for its ambitious growth targets in FY 2026-27.